Blockchain Registration Transaction Record

Incannex's Sleep Apnea Drug Shows 83% Efficacy in Phase 2 Trial

Incannex Healthcare's IHL-42X shows 83% efficacy in Phase 2 sleep apnea trial. Stonegate Capital updates coverage as company advances toward FDA discussions and late-stage development planning for 2026.

This development matters because obstructive sleep apnea affects approximately 30 million Americans and is linked to serious health complications including cardiovascular disease, stroke, and diabetes. Current treatments like CPAP machines have notoriously low compliance rates, leaving millions of patients without effective solutions. IHL-42X's impressive 83% reduction in apnea events, combined with strong patient-reported improvements in sleep quality and daily functioning, represents a potential breakthrough in sleep medicine. If approved, this oral medication could transform OSA treatment by offering a convenient alternative to mechanical devices, potentially improving treatment adherence and patient outcomes significantly. For investors, the successful Phase 2 results and strong financial position position Incannex as an emerging leader in sleep disorder therapeutics with multiple additional pipeline assets in anxiety and inflammatory conditions.